PYOTT DAVID E I 4
4 · ALNYLAM PHARMACEUTICALS, INC. · Filed Mar 25, 2025
Insider Transaction Report
Form 4
PYOTT DAVID E I
Director
Transactions
- Exercise/Conversion
Common Stock
2025-03-24$88.95/sh+7,440$661,788→ 7,576 total - Sale
Common Stock
2025-03-24$299.00/sh−7,440$2,224,560→ 136 total - Exercise/Conversion
Stock Option (right to buy)
2025-03-24−7,440→ 0 totalExercise: $88.95Exp: 2025-12-18→ Common Stock (7,440 underlying)
Holdings
- 27,900(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 5, 2024. The options exercised and sold by the reporting person were due to expire on December 18, 2025.
- [F2]The shares of ALNY common stock were purchased by the David E I Pyott Trust, of which the reporting person is trustee.
- [F3]This stock option was fully vested and exercisable as of December 18, 2016.